| Literature DB >> 22984459 |
Zahara Ali1, Aastha Mishra, Rahul Kumar, Perwez Alam, Priyanka Pandey, Rekhbala Ram, Tashi Thinlas, Ghulam Mohammad, M A Qadar Pasha.
Abstract
BACKGROUND: The interactions among various biomarkers remained unexplored under the stressful environment of high-altitude. Present study evaluated interactions among biomarkers to study susceptibility for high altitude pulmonary edema (HAPE) in HAPE-patients (HAPE-p) and adaptation in highland natives (HLs); both in comparison to HAPE-free sojourners (HAPE-f). METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2012 PMID: 22984459 PMCID: PMC3439466 DOI: 10.1371/journal.pone.0044049
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of the HAPE-p, HAPE-f and HLs.
| Clinical characteristics | HAPE-p | HAPE-f | HLs | p value | |
| HAPE-p vs HAPE-f | HLs vs HAPE-f | ||||
| n | 200 | 200 | 450 | ||
| SBP, mmHg | 124.6±21.1 | 119.8±3.5 | 128.1±24.0 | 0.007 | <0.0001 |
| DBP, mmHg | 82.7±17.0 | 80.4±10.0 | 84.1±15.0 | 0.099 | 0.001 |
| MAP, mmHg | 96.7±16.0 | 93.5±10.0 | 96.4±10.0 | 0.016 | 0.0006 |
| RR, rate/min | 24.7±6.2 | 22.6±3.2 | - | <0.0001 | - |
| PR, rate/min | 92.2±22.9 | 80.1±19.9 | 84.0±15.7 | <0.0001 | 0.007 |
| SaO2, % | 69.0±13.5 | 91.0±3.9 | 87.0±5.6 | <0.0001 | <0.0001 |
| PASP, mmHg | 45.0±8.3 | 25.9±1.1 | - | <0.0001 | - |
Data are presented as mean ± standard deviation and are compared by Student's t-test. n, number of subjects; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RR, respiratory rate; PR, pulse rate; SaO2, arterial oxygen saturation; PASP, pulmonary artery systolic pressure.
Baseline characteristics of the HAPE-p, HAPE-f and HLs.
| p value | |||||
| Baseline characteristics | HAPE-p | HAPE-f | HLs | HAPE-p vs HAPE-f | HLs vs HAPE-f |
| n | 200 | 200 | 450 | ||
| Age, yrs | 27.7±8.5 | 26.16±5.8 | 36.0±2.1 | 0.03 | <0.0001 |
| Height, cm | 166.0±7.1 | 162.0±6.9 | 159.0±5.1 | <0.0001 | <0.0001 |
| Weight, Kg | 60.0±10.0 | 50.0±7.1 | 52.0±6.1 | <0.0001 | 0.0002 |
| BMI, Kg/m2 | 21.1±3.8 | 19.22±2.7 | 20.3±2.6 | <0.0001 | <0.0001 |
| Number of visits | ≤1 | ≥3 | Residents | ||
Data are presented as mean ± standard deviation and are compared by Student's t-test. n, number of subjects; BMI, body mass index.
Plasma levels of biomarkers in HAPE-p and HAPE–f and HLs.
| Biomarkers | HAPE-p | HAPE-f | HLs | p value | |
| HAPE-p vs HAPE-f | HLs vs HAPE-f | ||||
| ADMA, nmol/mL | 4.57±2.92 (200) | 1.09±0.46 (200) | 1.88±0.82 (200) | <0.0001 | <0.0001 |
| 5-HT, ng/mL | 5.50±1.10 (200) | 3.60±1.40 (200) | 4.30±2.20 (450) | <0.0001 | <0.0001 |
| 8-iso PGF2α, pg/mL | 8.90±1.60 (200) | 6.04±0.89 (200) | 7.90±0.73 (450) | <0.0001 | <0.0001 |
| ET-1, pg/mL | 8.10±2.50 (63) | 3.60±0.870 (200) | 1.72±0.95 (200) | <0.0001 | <0.0001 |
| PRA, ng/ml/h | 1.64±0.95 (63) | 0.70±0.12 (200) | 0.95±0.21 (200) | 0.02 | 0.04 |
| PAC, pmol/L | 318.6±275 (63) | 166.9±98.0 (200) | 268.6±120 (200) | <0.0001 | <0.0001 |
| SOD, U/mL | 0.84±0.41 (200) | 1.40±0.360 (200) | 1.22±0.52 (450) | 0.001 | 0.40 |
| NO, µM/L | 57.67±30.12 (200) | 73.75±35.26 (200) | 122.4±70.0 (200) | <0.0001 | <0.0001 |
Data are presented as mean ± standard deviation and are compared by one–way ANOVA. n, number of subjects; ADMA, asymmetric dimethylarginine; 5-HT, serotonin; 8-isoPGF2α, 8-iso-prostaglandin-F2α; ET-1, endothelin-1; PRA, plasma renin activity; PAC, plasma aldosterone concentration; SOD, superoxide dismutase; NO, nitric oxide. The p values are adjusted with age, gender and BMI.
Figure 1Relative gene expression by real-time PCR expressed as fold change in HAPE-p and HLs.
Bars (mean ± SD) above the base line show upregulation and bars below the base line show downregulation. The differential expression (+/−) varied between 1.01–5.2. TPH-1, tryptophan hydroxylase-1; ET-1, endothelin-1; REN, renin; CYP11B2, cytochrome P450, family 11, subfamily B, polypeptide 2; SOD, superoxide dismutase; NOS3, nitric oxide synthase 3; HAPE-p, high altitude pulmonary edema patients; HLs, healthy highland natives; HAPE-f, High altitude pulmonary edema free sojourners. The comparisons of HAPE-p and HLs were made against HAPE-f.
Figure 2Clinical correlations in the three groups i.e. HAPE-p, HAPE-f and HLs.
An inverse correlation was obtained between the clinical parameters viz MAP and SaO2 in the three groups; MAP, mmHg; SaO2, %.
Figure 3Schematic presentation of the studied biomarkers in a physiological function under hypobaric hypoxia.
Interactions of several of these biomarkers that translate into the incidence of HAPE are also interpretable through the renin–angiotensin–aldosterone system, Kinin–kallikrein system, and the pathways of ET-1, 5-HT, NO signaling and oxidative-stress. ADMA, asymmetric dimethylarginine; ATII, angiotensin II; AT-1R, angiotensin-II type I receptor; AT-2R, angiotensin-II type II receptor; AngI, angiotensin I; AngII, angiotensin II; ACE, angiotensin-I converting enzyme; AGT, angiotensinogen; 8-isoPGF2α, 8-iso-prostaglandinF2α; ROS, reactive oxygen species; SOD, superoxide dismutase; O2˙-, superoxide anion; ONOO−, peroxynitrite; 5-HT, serotonin; ET-1, endothelin-1; ET-A and ET-B, endothelin receptors A and B; NO, nitric oxide; NOS3, endothelial nitric oxide synthase; VSMC, vascular smooth muscle cell; H2O2, hydrogen peroxide; H2O, water; EFA, essential fatty acids.